Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 of tegilidine for suppressing tracheal intubation response in elderly patients
ChiCTR2600129510Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Tegilidine in None (2 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: ED95 of tegilidine for attenuating tracheal intubation response in elderly patients. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Tegilidine
Beyond the preview
Go deeper on ChiCTR2600129510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129510.